Biotech and Drug Stocks
7.45k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called Battling Cancer.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
|---|---|---|---|---|
| Biotech and Drug Stocks | +1.01% | - | - | - |
| ^GSPC | +1.17% | +5.08% | +29.15% | +5607.69% |
31 Symbols
| Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 787.02 | +24.34 | +3.19% | 4:00 p.m. EDT | 2.71M | 2.85M | 747.99B |
| NVO | Novo Nordisk A/S | 134.66 | +1.74 | +1.31% | 4:00 p.m. EDT | 3.71M | 4.69M | 599.89B |
| JNJ | Johnson & Johnson | 152.67 | +1.29 | +0.85% | 4:00 p.m. EDT | 5.37M | 7.52M | 367.43B |
| MRK | Merck & Co., Inc. | 131.73 | +3.07 | +2.39% | 4:00 p.m. EDT | 7.22M | 8.25M | 335.28B |
| ABBV | AbbVie Inc. | 163.79 | +2.20 | +1.36% | 4:00 p.m. EDT | 5.26M | 5.66M | 289.23B |
| AZN | AstraZeneca PLC | 76.97 | -0.07 | -0.09% | 4:00 p.m. EDT | 3.85M | 5.62M | 239.96B |
| NVS | Novartis AG | 103.22 | -0.09 | -0.09% | 4:00 p.m. EDT | 1.05M | 1.63M | 210.61B |
| RHHBY | Roche Holding AG | 31.4 | +0.45 | +1.45% | 4:00 p.m. EDT | 1.19M | 2.85M | 205.80B |
| AMGN | Amgen Inc. | 319.04 | +7.63 | +2.45% | 4:00 p.m. EDT | 3.46M | 2.79M | 171.14B |
| PFE | Pfizer Inc. | 28.82 | +0.44 | +1.55% | 4:01 p.m. EDT | 34.60M | 42.74M | 163.66B |
| SNY | Sanofi | 49.01 | -0.49 | -0.99% | 4:00 p.m. EDT | 4.25M | 1.98M | 125.81B |
| VRTX | Vertex Pharmaceuticals Incorporated | 437.49 | +8.90 | +2.08% | 4:00 p.m. EDT | 1.06M | 1.02M | 113.25B |
| REGN | Regeneron Pharmaceuticals, Inc. | 978.21 | -6.43 | -0.65% | 4:00 p.m. EDT | 590.22k | 453.61k | 106.94B |
| GSK | GSK plc | 45.7 | +0.04 | +0.09% | 4:00 p.m. EDT | 3.77M | 3.15M | 93.50B |
| BMY | Bristol-Myers Squibb Company | 44.55 | -0.16 | -0.36% | 4:00 p.m. EDT | 8.31M | 15.36M | 91.01B |
| GILD | Gilead Sciences, Inc. | 67.01 | -0.64 | -0.95% | 4:00 p.m. EDT | 7.53M | 7.15M | 83.48B |
| ZTS | Zoetis Inc. | 173.28 | +4.41 | +2.61% | 4:00 p.m. EDT | 2.58M | 3.74M | 79.07B |
| MRNA | Moderna, Inc. | 129.06 | +0.74 | +0.58% | 4:00 p.m. EDT | 2.94M | 3.86M | 49.46B |
| TAK | Takeda Pharmaceutical Company Limited | 13.39 | -0.06 | -0.45% | 4:00 p.m. EDT | 1.10M | 1.67M | 42.02B |
| HLN | Haleon plc | 8.41 | +0.09 | +1.08% | 4:00 p.m. EDT | 8.86M | 6.32M | 38.40B |
| BIIB | Biogen Inc. | 235.32 | +8.44 | +3.72% | 4:00 p.m. EDT | 1.79M | 1.25M | 34.26B |
| BAYRY | Bayer Aktiengesellschaft | 8.015 | +0.05 | +0.56% | 3:59 p.m. EDT | 980.55k | 2.10M | 31.50B |
| ARGX | argenx SE | 376.96 | +20.95 | +5.88% | 4:00 p.m. EDT | 343.79k | 273.53k | 23.60B |
| BNTX | BioNTech SE | 92.2 | -0.08 | -0.09% | 4:00 p.m. EDT | 467.64k | 595.48k | 22.33B |
| GMAB | Genmab A/S | 30.22 | +0.69 | +2.34% | 4:00 p.m. EDT | 512.82k | 534.35k | 19.52B |
| TEVA | Teva Pharmaceutical Industries Limited | 16.78 | -0.31 | -1.81% | 4:00 p.m. EDT | 12.44M | 9.97M | 19.01B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 147.4 | -0.49 | -0.33% | 4:00 p.m. EDT | 536.14k | 691.86k | 18.90B |
| BGNE | BeiGene, Ltd. | 164.88 | +4.11 | +2.56% | 4:00 p.m. EDT | 130.61k | 212.20k | 18.70B |
| ALPMY | Astellas Pharma Inc. | 9.8 | +0.06 | +0.62% | 3:53 p.m. EDT | 222.39k | 332.16k | 17.57B |
| RPRX | Royalty Pharma plc | 28.21 | +0.14 | +0.50% | 4:00 p.m. EDT | 1.89M | 2.78M | 17.04B |
Investor's Business DailyDow Jones Futures: Dow, S&P 500, Nasdaq Hit Highs, Nvidia Leads 12 New Buys; What To Do Now
The Dow, S&P 500 and Nasdaq hit record highs on tame inflation data. Nvidia broke out, leading new buys.
PR NewswireAMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice president of Research and Development and chief
- Reuters
UPDATE 2-US FDA approves expanded use of Bristol Myers' cancer cell therapy
The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular lymphoma, that has returned or has not responded to prior treatments. The Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat patients with the type of blood cancer who have received two or more prior lines of therapy. Breyanzi was first approved in the United States in 2021 as a second-line treatment for a type of blood cancer known as large B-cell lymphoma.
